HealthQuill Pfizer Inc
Pfizer Inc. stopped its trial of danuglipron for treating chronic weight management after an asymptomatic patient developed a drug-induced liver injury that was resolved after discontinuation of the oral drug.
Uncategorized

Pfizer stops development of an investigational drug to treat obesity

HQ Team April 15, 2025: Pfizer Inc. stopped its trial of danuglipron for treating chronic weight management after an asymptomatic patient developed a.

Read More
Pizer Inc.’s late-stage trial of an antibody treatment for a certain type of bladder cancer has shown significant improvement in time patients remained free of complications, according to a company statement.
Drugs Health Medical

Pfizer’s trial antibody for type of bladder cancer meets main goal

Pizer Inc.’s late-stage trial of an antibody treatment for a certain type of bladder cancer has shown significant improvement in time patients remained.

Read More
fizer Inc.’s combination drug to treat a type of metastatic colorectal cancer has been approved by the US drug regulator, according to a company statement.
Drugs Medical Pharma

Pfizer’s drug to treat metastatic colorectal cancer gets US approval

fizer Inc.’s combination drug to treat a type of metastatic colorectal cancer has been approved by the US drug regulator, according to a.

Read More
The US Food and Drug Administration has greenlighted Pfizer Inc.’s respiratory syncytial virus vaccine (RSV) Abrysvo for treating lower respiratory tract disease in people 18-59 years.
Drugs Health Pharma

US drug regulator FDA approves expanded use of Pfizer’s RSV vaccine

The US Food and Drug Administration has greenlighted Pfizer Inc.’s respiratory syncytial virus vaccine (RSV) Abrysvo for treating lower respiratory tract disease in.

Read More
Pfizer Inc., got a nod from the US drug regulator for its drug Hympavzi to treat two types of a rare blood disorder in haemophilia patients.
Drugs Health Pharma

Pfizer’s drug to treat rare haemophilia disorder gets US regulator’s approval

Pfizer Inc., got a nod from the US drug regulator for its drug Hympavzi to treat two types of a rare blood disorder.

Read More
Pfizer Inc.’s sickle cell therapy involving Oxbryta has been voluntarily withdrawn from global markets due to painful complications and death, according to a company statement.
Drugs Health Pharma

Pfizer pulls out sickle cell therapy from global markets, cites death, snags

Pfizer Inc.’s sickle cell therapy involving Oxbryta has been voluntarily withdrawn from global markets due to painful complications and death, according to a.

Read More
The US Food and Drug Administration has granted emergency use authorisation to the Covid-19 vaccine made by Pfizer Inc., and ModernaTX Inc., which incorporates a new component to fight a variant of the virus.
Drugs Health Pharma

FDA approves new Covid-19 jabs before fall and winter in the United States

The US Food and Drug Administration has granted emergency use authorisation to the Covid-19 vaccine made by Pfizer Inc., and ModernaTX Inc., which.

Read More
Pfizer Inc., a US pharmaceutical and biotechnology corporation, announced its single dose of respiratory syncytial virus (RSV) vaccine would maintain protection from the disease through to a second season.
Drugs Health Pharma

Pfizer says RSV vaccine can ensure protection into second season

HQ Team March 1, 2024: Pfizer Inc., a US pharmaceutical and biotechnology corporation, announced its single dose of respiratory syncytial virus (RSV) vaccine.

Read More
Pfizer is expected to close the $43 billion acquisition of Seagen by Thursday as the company announced restructuring its business and management.
Drugs Health Pharma

Pfizer revamps organisation as $43 billion Seagen deal comes to close

HQ Team December 13, 2023: Pfizer is expected to close the $43 billion acquisition of Seagen by Thursday as the company announced restructuring.

Read More
Pfizer Inc., has discontinued its clinical trials of the twice-daily oral weight-loss drug, danuglipron, after more than 50% of the patients opted out due to adverse effects of the medicine.
Drugs Health Pharma

Pfizer Inc., stops twice-daily oral obesity drug trial at mid-stage

HQ Team December 2, 2023: Pfizer Inc., has discontinued its clinical trials of the twice-daily oral weight-loss drug, danuglipron, after more than 50%.

Read More